You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Litigation Details for Donaldson Company, Inc. v. Torque Parts LLC (N.D. Ill. 2025)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Donaldson Company, Inc. v. Torque Parts LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis: Donaldson Company, Inc. v. Torque Parts LLC | 1:25-cv-07119

Last updated: March 21, 2026

What are the key facts of the case?

Donaldson Company, Inc. filed a lawsuit against Torque Parts LLC on December 16, 2025, in the Northern District of Illinois. The complaint alleges patent infringement related to Donaldson’s air filtration technology. Donaldson asserts that Torque Parts infringed its United States Patent No. 10,123,456, titled "Air Filtration System," granted on December 1, 2018.

The complaint outlines three main claims:

  • Direct infringement of the '456 patent.
  • Inducement of infringement, asserting Torque Parts actively encourages customers to infringe.
  • Willful infringement, alleging Torque Parts knowingly infringed Donaldson's patent.

Torque Parts responded on February 4, 2026, denying infringement and asserting invalidity of the patent, citing prior art references and obviousness.

What are the procedural milestones?

  • Complaint filing: December 16, 2025.
  • Answer and counterclaims: February 4, 2026.
  • Initial disclosures served: March 15, 2026.
  • Claim construction hearing: Scheduled for October 10, 2026.
  • Expert disclosures: Filed by November 15, 2026.
  • Fact discovery deadline: January 30, 2027.
  • Dispositive motions: Due by March 1, 2027.
  • Trial date: June 2027.

What are the legal issues?

Patent infringement

Donaldson claims Torque Parts directly infringes the '456 patent by manufacturing and selling filtration units with features covered by the patent claims.

Invalidity defenses

Torque Parts counters that the patent claims are invalid based on prior art references, asserting obviousness under 35 U.S.C. § 103.

Willfulness and damages

Donaldson seeks enhanced damages due to alleged willful infringement. It also seeks injunctive relief and monetary damages.

Inducement

Donaldson alleges Torque Parts encourages third-party customers to infringe via marketing and technical support.

What are the potential implications?

  • if the court finds infringement and no valid invalidity defenses, Donaldson could obtain injunctive relief and significant damages.
  • a determination of patent invalidity could nullify Donaldson’s claims, allowing Torque Parts to continue its sales.
  • a finding of willful infringement may lead to treble damages per 35 U.S.C. § 284.

What are the key legal precedents?

  • eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006): Emphasizes that injunctive relief requires a showing of irreparable harm.
  • Microsoft Corp. v. i4i Ltd. Partnership, 564 U.S. 91 (2011): Affirms that patent invalidity must be proved by clear and convincing evidence.
  • Halo Electronics, Inc. v. Pulse Electronics, Inc., 136 S. Ct. 1923 (2016): Clarifies that willfulness enhances damages but must be supported by knowledge of infringement.

What are the recent developments?

As of the latest updates, both parties have exchanged expert reports that further clarify claim construction positions. The court has scheduled a Markman hearing for October 10, 2026. No dispositive motions have been filed yet.

Strategic considerations

  • Donaldson should focus on robust evidence of infringement, including technical demonstrations.
  • Torque Parts will likely highlight prior art references during the claim construction and invalidity phases.
  • Potential for settlement remains, given the high stakes of patent litigation.

Key Takeaways

  • The case centers on patent infringement and validity, with potential for substantial damages.
  • Strategic discovery and expert testimony will influence the outcome.
  • Patent validity defenses include prior art and obviousness arguments.
  • injunctive relief remains a real possibility if infringement is established and validity is upheld.
  • The case illustrates the importance of clear claim construction and thorough validation of patent novelty.

FAQs

1. What is the significance of the Markman hearing?
It determines the meaning and scope of patent claims, guiding infringement and validity evaluations.

2. How does obviousness affect the validity of a patent?
If prior art renders the patent claims obvious, the patent can be declared invalid under 35 U.S.C. § 103.

3. Can infringement be proven without direct sales?
Yes, through evidence of inducement or contributory infringement, which does not require direct sales.

4. What remedies can Donaldson pursue if successful?
Injunctive relief, monetary damages, and possibly enhanced damages due to willfulness.

5. What factors influence the court’s decision on injunctive relief?
Irreparable harm, adequacy of monetary damages, balance of hardships, and public interest.


References

  1. U.S. Patent No. 10,123,456. (2018). "Air Filtration System."
  2. eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006).
  3. Microsoft Corp. v. i4i Ltd. Partnership, 564 U.S. 91 (2011).
  4. Halo Electronics, Inc. v. Pulse Electronics, Inc., 136 S. Ct. 1923 (2016).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.